Q1 FY2026 · ended Mar 31, 2026 · Revenue $2.95M, -47.2% YoY · Filed May 15, 2026
Allurion Technologies, Inc. (ALUR) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In Q1 of fiscal 2026, the quarter ended Mar 31, 2026, it reported revenue of $2.9 million and a net loss of $6.1 million. As of Mar 31, 2026 it held $5.1 million in cash and investments and $896,000 in total debt.
Revenue
$2.95M
-47.2% vs year-ago quarter
Net income
$-6.09M
-306.1% vs year-ago quarter
Operating cash flow
$-3.22M
+66.0% vs year-ago quarter
Free cash flow
$-13.27M
-9.9% vs prior quarter
EPS
$-0.46
-48.4% vs year-ago quarter
Dividend per share
None
Shares outstanding
15.01M
+101.2% vs year-ago quarter
Net cash
$4.16M
Q1 FY2026
Operating margin
-211.2%
TTM
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- ALUR (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Natick, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1964979
- Former names
- ALLURION TECHNOLOGIES HOLDINGS, INC. (until Aug 1, 2023)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
Q1 FY2025 Mar 31, 2025 |
|---|---|---|---|---|---|
| Revenue | $2.9M | $3.6M | $2.7M | $3.4M | $5.6M |
| Operating income | -$3.7M | -$6.3M | -$9.6M | -$7.0M | -$7.3M |
| Net income | -$6.1M | -$6.0M | -$11.9M | -$9.3M | -$1.5M |
| Diluted EPS | -$0.46 | -$0.59 | -$1.53 | -$1.28 | -$0.31 |
| Operating cash flow | -$3.2M | -$5.3M | -$6.5M | -$7.6M | -$9.5M |
| Total assets | $14.0M | $15.8M | $18.1M | $28.2M | $38.4M |
| Total liabilities | $91.9M | $93.0M | $101.1M | $92.1M | $108.2M |
| Stockholders' equity | -$77.9M | -$77.2M | -$82.9M | -$64.0M | -$69.8M |
| Cash and investments | $5.1M | $5.4M | $6.1M | $12.7M | $20.4M |
| Total debt | $896,000 | $969,000 | $1.2M | $30.5M | $33.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Aug 24, 2026 | Aug 17, 2026 |
| 8-K |
Current report
Material agreement, Agreement ended, Unregistered share sale
|
Jul 24, 2026 | Jul 21, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 23, 2026 | Jul 17, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 7, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 30, 2026 | Jun 24, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change, Other events
|
Jun 17, 2026 | Jun 12, 2026 |
All 318 Allurion Technologies, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.